Tehila Ben Moshe

Tehila is the founder of Biond Biologis and had served as Biond’s CEO and Board of Directors chairperson since the company’s inception. She brings over a decade of scientific excellence and entrepreneurial leadership in biotech and pharma, combined with proven leadership skills and business acumen. Prior to founding Biond, Tehila was the CEO of cCAM Biotherapeutics and led the immuno-oncology company from launch through drug discovery and development and early stage clinical trials. The company was subsequently acquired by Merck (MSD) in 2015. cCAM was the first Israeli biotech companies to be acquired by a top pharma based on pre-clinical data, generating 10X return to investors in less than 3 years. Prior to her entrepreneurial career, Tehila led R&D projects at Protalix Biotherapeutics (NYSE/TASE: PLX) driving the development of ‘Bio-Better’ proteins from early stage up to clinic trials. Tehila holds a Ph.D. in Biochemistry from the Weizmann Institute where she studied immune signaling pathways in health and disease. She is the author of multiple patents and peer-reviewed scientific publications.